Search

Your search keyword '"McLean, Huong Q."' showing total 194 results
Start Over Author "McLean, Huong Q." Search Limiters Available in Library Collection
194 results on '"McLean, Huong Q."'

1. Work Attendance with Acute Respiratory Illness Before and During COVID-19 Pandemic, United States, 2018-2022

Author

Ahmed, Faruque, Nowalk, Mary Patricia, Zimmerman, Richard K., Bear, Todd, Grijalva, Carlos G., Talbot, H. Keipp, Florea, Ana, Tartof, Sara Y., Gaglani, Manjusha, Smith, Michael, McLean, Huong Q., King, Jennifer P., Martin, Emily T., Monto, Arnold S., Phillips, C. Hallie, Wernli, Karen J., Flannery, Brendan, Chung, Jessie R., and Uzicanin, Amra

Subjects
Epidemics -- Statistics -- Risk factors -- United States, Respiratory tract diseases -- Statistics -- Risk factors, Influenza -- Statistics -- Risk factors, Presenteeism (Labor) -- Statistics -- Health aspects, Health
Abstract

COVID-19 cases in the United States, first reported on January 22, 2020, began to increase in March 2020 (1). The pandemic resulted in a substantial number of employed persons being [...]

Published
2023
Full Text
View/download PDF

5. Interim Estimates of 2019–20 Seasonal Influenza Vaccine Effectiveness — United States, February 2020

Author

Dawood, Fatimah S., Chung, Jessie R., Kim, Sara S., Zimmerman, Richard K., Nowalk, Mary Patricia, Jackson, Michael L., Jackson, Lisa A., Monto, Arnold S., Martin, Emily T., Belongia, Edward A., McLean, Huong Q., Gaglani, Manjusha, Dunnigan, Kayan, Foust, Angie, Sessions, Wendy, DaSilva, Juliana, Le, Shoshona, Stark, Thomas, Kondor, Rebecca J., Barnes, John R., Wentworth, David E., Brammer, Lynnette, Fry, Alicia M., Patel, Manish M., and Flannery, Brendan

Published
2020

6. Interim Estimates of 2018–19 Seasonal Influenza Vaccine Effectiveness — United States, February 2019

Author

Doyle, Joshua D., Chung, Jessie R., Kim, Sara S., Gaglani, Manjusha, Raiyani, Chandni, Zimmerman, Richard K., Nowalk, Mary Patricia, Jackson, Michael L., Jackson, Lisa A., Monto, Arnold S., Martin, Emily T., Belongia, Edward A., McLean, Huong Q., Foust, Angie, Sessions, Wendy, Berman, LaShondra, Garten, Rebecca J., Barnes, John R., Wentworth, David E., Fry, Alicia M., Patel, Manish M., and Flannery, Brendan

Published
2019

9. Interim Estimates of 2022-23 Seasonal Influenza Vaccine Effectiveness-- Wisconsin, October 2022-February 2023

Author

McLean, Huong Q., Petrie, Joshua G., Hanson, Kayla E., Meece, Jennifer K., Rolfes, Melissa A., Sylvester, Gregg C., Neumann, Gabriele, Kawaoka, Yoshihiro, and Belongia, Edward A.

Subjects
Influenza vaccines, Influenza, Health
Abstract

In the United States, 2022-23 influenza activity began earlier than usual, increasing in October 2022, and has been associated with high rates of hospitalizations among children * (1). Influenza A(H3N2) [...]

Published
2023

11. Safety of measles, mumps, and rubella vaccine in adolescents and adults in the vaccine safety Datalink

Author

Hanson, Kayla E., primary, Marin, Mona, additional, Daley, Matthew F., additional, Groom, Holly C., additional, Jackson, Lisa A., additional, Sy, Lina S., additional, Klein, Nicola P., additional, DeSilva, Malini B., additional, Panagiotakopoulos, Lakshmi, additional, Weintraub, Eric, additional, Belongia, Edward A., additional, and McLean, Huong Q., additional

Published
2023
Full Text
View/download PDF

12. Effectiveness of first and second COVID‐19 mRNA vaccine monovalent booster doses during a period of circulation of Omicron variant sublineages: December 2021–July 2022

Author

Petrie, Joshua G., primary, King, Jennifer P., additional, McClure, David L., additional, Rolfes, Melissa A., additional, Meece, Jennifer K., additional, Pattinson, David, additional, Neumann, Gabriele, additional, Kawaoka, Yoshihiro, additional, Belongia, Edward A., additional, and McLean, Huong Q., additional

Published
2023
Full Text
View/download PDF

13. Interim Estimates of 2021-22 Seasonal Influenza Vaccine Effectiveness--United States, February 2022

Author

Chung, Jessie R., Kim, Sara S., Kondor, Rebecca J., Smith, Catherine, Budd, Alicia P., Tartof, Sara Y., Florea, Ana, Talbot, H. Keipp, Grijalva, Carlos G., Wernli, Karen J., Phillips, C. Hallie, Monto, Arnold S., Martin, Emily T., Belongia, Edward A., McLean, Huong Q., Gaglani, Manjusha, Reis, Michael, Geffel, Krissy Moehling, Nowalk, Mary Patricia, DaSilva, Juliana, Keong, Lisa M., Stark, Thomas J., Barnes, John R., Wentworth, David E., Brammer, Lynnette, Burns, Erin, Fry, Alicia M., Patel, Manish M., and Flannery, Brendan

Subjects
Medical research, Medicine, Experimental, Vaccination, Influenza vaccines, Influenza, Health
Abstract

In the United States, annual vaccination against seasonal influenza is recommended for all persons aged >6 months except when contraindicated (1). Currently available influenza vaccines are designed to protect against [...]

Published
2022

22. Implications of Shortened Quarantine Among Household Contacts of Index Patients with Confirmed SARS-CoV-2 Infection--Tennessee and Wisconsin, April-September 2020

Author

Rolfes, Melissa A., Grijalva, Carlos G., Zhu, Yuwei, McLean, Huong Q., Hanson, Kayla E., Belongia, Edward A., Halasa, Natasha B., Kim, Ahra, Meece, Jennifer, Reed, Carrie, Talbot, H. Keipp, and Fry, Alicia M.

Subjects
Quarantine -- Health aspects, Infection -- Prevention, Health
Abstract

To prevent further transmission of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), CDC currently recommends that persons who have been in close contact with someone with SARS-CoV-2 infection [...]

Published
2021

25. Vaccine effectiveness against COVID‐19 among symptomatic persons aged ≥12 years with reported contact with COVID‐19 cases, February–September 2021

Author

Chung, Jessie R., primary, Kim, Sara S., additional, Belongia, Edward A., additional, McLean, Huong Q., additional, King, Jennifer P., additional, Nowalk, Mary Patricia, additional, Zimmerman, Richard K., additional, Moehling Geffel, Krissy, additional, Martin, Emily T., additional, Monto, Arnold S., additional, Lamerato, Lois E., additional, Gaglani, Manjusha, additional, Hoffman, Eric, additional, Volz, Marcus, additional, Jackson, Michael L., additional, Jackson, Lisa A., additional, Patel, Manish M., additional, and Flannery, Brendan, additional

Published
2022
Full Text
View/download PDF

27. Publishing interim early or mid-season influenza vaccine effectiveness – US Flu VE Network

Author

Chung, Jessie R., Flannery, Brendan, Kim, Sara S., Gaglani, Manjusha, Raiyani, Chandni, Belongia, Edward A., McLean, Huong Q., Nowalk, Mary Patricia, Zimmerman, Richard K., Jackson, Michael L., Jackson, Lisa A., Martin, Emily T., Monto, Arnold S., and Patel, Manish

Subjects
Influenza A Virus, H1N1 Subtype, Influenza Vaccines, Case-Control Studies, Influenza A Virus, H3N2 Subtype, Sample Size, Influenza, Human, Vaccination, Humans, Seasons, Article, United States, Aged
Abstract

INTRODUCTION: Mid-season influenza vaccine effectiveness (VE) estimates are a useful tool to help guide annual influenza vaccine strain selection, vaccine policy, and public health messaging. We propose using a sample size-driven approach with data-driven inputs for publication of mid-season influenza VE. METHODS: We used pooled inputs for VE by (sub)type and average vaccine coverage by age groups using data from eight seasons of the US Influenza VE Network to calculate sample sizes needed to estimate mid-season VE. RESULTS: We estimate that 135 influenza-positive cases would be needed to detect an overall VE of 40% with 55% vaccine coverage among test-negative controls. Larger sample sizes would be required to produce reliable estimates specifically against influenza A/H3N2 and for older age groups. CONCLUSION: Using an existing network, most of the recent influenza seasons in the US would facilitate valid mid-season VE estimates using the proposed sample sizes for broad age groupings.

Published
2021

28. Effectiveness of two and three mRNA COVID‐19 vaccine doses against Omicron‐ and Delta‐Related outpatient illness among adults, October 2021–February 2022.

Author

Kim, Sara S., Chung, Jessie R., Talbot, H. Keipp, Grijalva, Carlos G., Wernli, Karen J., Kiniry, Erika, Martin, Emily T., Monto, Arnold S., Belongia, Edward A., McLean, Huong Q., Gaglani, Manjusha, Mamawala, Mufaddal, Nowalk, Mary Patricia, Moehling Geffel, Krissy, Tartof, Sara Y., Florea, Ana, Lee, Justin S., Tenforde, Mark W., Patel, Manish M., and Flannery, Brendan

Subjects
COVID-19 vaccines, SARS-CoV-2 Omicron variant, COUGH, FLU vaccine efficacy, MESSENGER RNA, OUTPATIENT medical care, VACCINE effectiveness, SMELL
Abstract

Background: We estimated SARS‐CoV‐2 Delta‐ and Omicron‐specific effectiveness of two and three mRNA COVID‐19 vaccine doses in adults against symptomatic illness in US outpatient settings. Methods: Between October 1, 2021, and February 12, 2022, research staff consented and enrolled eligible participants who had fever, cough, or loss of taste or smell and sought outpatient medical care or clinical SARS‐CoV‐2 testing within 10 days of illness onset. Using the test‐negative design, we compared the odds of receiving two or three mRNA COVID‐19 vaccine doses among SARS‐CoV‐2 cases versus controls using logistic regression. Regression models were adjusted for study site, age, onset week, and prior SARS‐CoV‐2 infection. Vaccine effectiveness (VE) was calculated as (1 − adjusted odds ratio) × 100%. Results: Among 3847 participants included for analysis, 574 (32%) of 1775 tested positive for SARS‐CoV‐2 during the Delta predominant period and 1006 (56%) of 1794 participants tested positive during the Omicron predominant period. When Delta predominated, VE against symptomatic illness in outpatient settings was 63% (95% CI: 51% to 72%) among mRNA two‐dose recipients and 96% (95% CI: 93% to 98%) for three‐dose recipients. When Omicron predominated, VE was 21% (95% CI: −6% to 41%) among two‐dose recipients and 62% (95% CI: 48% to 72%) among three‐dose recipients. Conclusions: In this adult population, three mRNA COVID‐19 vaccine doses provided substantial protection against symptomatic illness in outpatient settings when the Omicron variant became the predominant cause of COVID‐19 in the United States. These findings support the recommendation for a third mRNA COVID‐19 vaccine dose. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

30. Systematic Testing for Influenza and Coronavirus Disease 2019 Among Patients With Respiratory Illness

Author

Flannery, Brendan, Meece, Jennifer K, Williams, John V, Martin, Emily T, Gaglani, Manjusha, Jackson, Michael L, Talbot, H Keipp, Belongia, Edward A, McLean, Huong Q, Zimmerman, Richard K, Nowalk, M Patricia, Johnson, Monika, Monto, Arnold S, Lamerato, Lois E, Malani, Anurag N, Phillips, C Hallie, Kiniry, Erika, Wellwood, Stacie, Volz, Marcus, Walker, Kimberly, Rao, Arundhati, Wyatt, Dayna, Trabue, Christopher, Zhu, Yuwei, Chung, Jessie R, Kim, Sara S, Ferdinands, Jill M, and Patel, Manish M

Subjects
Microbiology (medical), 2019-20 coronavirus outbreak, Respiratory illness, Respiratory tract infections, Coronavirus disease 2019 (COVID-19), Middle East respiratory syndrome coronavirus, business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), medicine.disease_cause, Virology, Systematic testing, Infectious Diseases, medicine, business
Published
2020
Full Text
View/download PDF

31. Role of Age in the Spread of Influenza, 2011–2019: Data From the US Influenza Vaccine Effectiveness Network.

Author

Griggs, Eric P, Flannery, Brendan, Foppa, Ivo M, Gaglani, Manjusha, Murthy, Kempapura, Jackson, Michael L, Jackson, Lisa A, Belongia, Edward A, McLean, Huong Q, Martin, Emily T, Monto, Arnold S, Zimmerman, Richard K, Balasubramani, Goundappa K, Chung, Jessie R, Patel, Manish, and Investigators, for the US Influenza Vaccine Effectiveness Study

Subjects
INFLUENZA epidemiology, INFLUENZA vaccines, DRUG efficacy, STATISTICS, AGE distribution, TREATMENT effectiveness, SEASONS, INFECTIOUS disease transmission, INFLUENZA, DATA analysis
Abstract

Intraseason timing of influenza infection among persons of different ages could reflect relative contributions to propagation of seasonal epidemics and has not been examined among ambulatory patients. Using data from the US Influenza Vaccine Effectiveness Network, we calculated risk ratios derived from comparing weekly numbers of influenza cases prepeak with those postpeak during the 2010–2011 through 2018–2019 influenza seasons. We sought to determine age-specific differences during the ascent versus descent of an influenza season by influenza virus type and subtype. We estimated 95% credible intervals around the risk ratios using Bayesian joint posterior sampling of weekly cases. Our population consisted of ambulatory patients with laboratory-confirmed influenza who enrolled in an influenza vaccine effectiveness study at 5 US sites during 9 influenza seasons after the 2009 influenza A virus subtype H1N1 (H1N1) pandemic. We observed that young children aged <5 years tended to more often be infected with H1N1 during the prepeak period, while adults aged ≥65 years tended to more often be infected with H1N1 during the postpeak period. However, for influenza A virus subtype H3N2, children aged <5 years were more often infected during the postpeak period. These results may reflect a contribution of different age groups to seasonal spread, which may differ by influenza virus type and subtype. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

37. Hospitalization following outpatient medical care for influenza: US influenza vaccine effectiveness network, 2011-12-2015-16

Author

Appiah, Grace D., primary, Chung, Jessie R., additional, Flannery, Brendan, additional, Havers, Fiona P., additional, Zimmerman, Richard K., additional, Nowalk, Mary Patricia, additional, Monto, Arnold S., additional, Martin, Emily T., additional, Gaglani, Manjusha, additional, Murthy, Kempapura, additional, Jackson, Lisa A., additional, Jackson, Michael L., additional, McLean, Huong Q., additional, Belongia, Edward A., additional, and Fry, Alicia M., additional

Published
2018
Full Text
View/download PDF

38. Effect of Previous-Season Influenza Vaccination on Serologic Response in Children During 3 Seasons, 2013–2014 Through 2015–2016.

Author

McLean, Huong Q, King, Jennifer P, Talley, Pamela, Flannery, Brendan, Spencer, Sarah, Levine, Min Z, Friedrich, Thomas C, and Belongia, Edward A

Subjects
*HEMAGGLUTINATION tests, *INFLUENZA vaccines, *SEASONS, *VIRAL antibodies, *VIRAL antigens, *SEASONAL influenza, *ANTIBODY formation, *CHILDREN
Abstract

Background The effects of repeated influenza vaccination in children are not well understood. In this study, we evaluated previous vaccination effects on antibody response after vaccination with trivalent inactivated influenza vaccine (IIV) or quadrivalent live-attenuated influenza vaccine (LAIV) among school-aged children (5–17 years) across 3 seasons. Methods Children were enrolled in the fall of 2013, 2014, and 2015. The participants received IIV or LAIV according to parent preference (2013–2014) or our randomization scheme (2014–2015). All study children received IIV in 2015–2016. Hemagglutination-inhibition assays measured antibody response to egg-grown vaccine strains from prevaccination and postvaccination serum samples. Geometric mean titers (GMTs) and increases in GMTs from before to after vaccination (geometric mean fold rise [GMFR]) were estimated from repeated-measures linear mixed models. Results We enrolled 161 children in 2013–2014, 128 in 2014–2015, and 126 in 2015–2016. Among the IIV recipients, responses to the influenza A(H1N1)pdm09 and B vaccine strains were lowest among children who had received a previous-season IIV. The GMFRs for strains A(H1N1)pdm09 and B were 1.5 to 2.3 for previous-season IIV and 4.3 to 12.9 for previous-season LAIV or no previous vaccine. GMFRs were lower for strain A(H3N2), and differences according to previous-season vaccination history were smaller and not significant in most seasons. Most children had a post-IIV vaccination titer of ≥40 for vaccine strains in all seasons, regardless of previous-season vaccination history. Little to no increase in antibody levels was observed after vaccination with LAIV. Conclusions Serologic response to vaccination was greatest for IIV, but previous-season vaccination modified IIV response to A(H1N1)pdm09 and B. Influenza A(H3N2) responses were low in all groups, and LAIV generated minimal serologic response against all strains. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

41. Outpatient Antibiotic Prescribing for Acute Respiratory Infections During Influenza Seasons

Author

Havers, Fiona P., primary, Hicks, Lauri A., additional, Chung, Jessie R., additional, Gaglani, Manjusha, additional, Murthy, Kempapura, additional, Zimmerman, Richard K., additional, Jackson, Lisa A., additional, Petrie, Joshua G., additional, McLean, Huong Q., additional, Nowalk, Mary Patricia, additional, Jackson, Michael L., additional, Monto, Arnold S., additional, Belongia, Edward A., additional, Flannery, Brendan, additional, and Fry, Alicia M., additional

Published
2018
Full Text
View/download PDF

42. Interim estimates of 2017–18 seasonal influenza vaccine effectiveness — United States, February 2018

Author

Flannery, Brendan, primary, Chung, Jessie R., additional, Belongia, Edward A., additional, McLean, Huong Q., additional, Gaglani, Manjusha, additional, Murthy, Kempapura, additional, Zimmerman, Richard K., additional, Nowalk, Mary Patricia, additional, Jackson, Michael L., additional, Jackson, Lisa A., additional, Monto, Arnold S., additional, Martin, Emily T., additional, Foust, Angie, additional, Sessions, Wendy, additional, Berman, LaShondra, additional, Barnes, John R., additional, Spencer, Sarah, additional, and Fry, Alicia M., additional

Published
2018
Full Text
View/download PDF

45. Influenza Vaccine Effectiveness among Elderly and Non-Elderly Adults Aged ≥45 Years in the United States, 2011–2012 to 2015–2016

Author

Havers, Fiona P, primary, Russell, Kate, additional, Chung, Jessie, additional, Monto, Arnold S, additional, Martin, Emily T, additional, Belongia, Edward A, additional, McLean, Huong Q, additional, Gaglani, Manjusha, additional, Murthy, Kempapura, additional, Zimmerman, Richard K, additional, Nowalk, Mary Patricia, additional, Jackson, Michael L, additional, Jackson, Lisa A, additional, and Flannery, Brendan L, additional

Published
2017
Full Text
View/download PDF

48. Influenza Vaccine Effectiveness in the United States During the 2016–2017 Season

Author

Flannery, Brendan, primary, Chung, Jessie, additional, Monto, Arnold S, additional, Martin, Emily T, additional, Belongia, Edward, additional, Mclean, Huong Q, additional, Gaglani, Manjusha, additional, Murthy, Kempapura, additional, Zimmerman, Richard, additional, Nowalk, Mary Patricia, additional, Jackson, Michael L, additional, Jackson, Lisa A, additional, Spencer, Sarah, additional, and Fry, Alicia M, additional

Published
2017
Full Text
View/download PDF

49. Hospitalization following outpatient medical care for influenza: US influenza vaccine effectiveness network, 2011‐12—2015‐16.

Author

Appiah, Grace D., Chung, Jessie R., Flannery, Brendan, Havers, Fiona P., Zimmerman, Richard K., Nowalk, Mary Patricia, Monto, Arnold S., Martin, Emily T., Gaglani, Manjusha, Murthy, Kempapura, Jackson, Lisa A., Jackson, Michael L., McLean, Huong Q., Belongia, Edward A., and Fry, Alicia M.

Subjects
OUTPATIENT medical care, HOSPITAL care, INFLUENZA vaccines, SARS disease, INFLUENZA, REVERSE transcriptase polymerase chain reaction
Abstract

Over five seasons, we determined the proportion of outpatients with laboratory‐confirmed, influenza‐associated illness who were hospitalized within 30 days following the outpatient visit. Overall, 136 (1.7%) of 7813 influenza‐positive patients were hospitalized a median of 4 days after an outpatient visit. Patients aged ≥ 65 years and those with high‐risk conditions were at increased risk of hospitalization. After controlling for age and high‐risk conditions, vaccination status and infecting influenza virus type were not associated with hospitalization risk among adults. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

50. Classification and Regression Tree (CART) analysis to predict influenza in primary care patients

Author

Zimmerman, Richard K., primary, Balasubramani, G. K., additional, Nowalk, Mary Patricia, additional, Eng, Heather, additional, Urbanski, Leonard, additional, Jackson, Michael L., additional, Jackson, Lisa A., additional, McLean, Huong Q., additional, Belongia, Edward A., additional, Monto, Arnold S., additional, Malosh, Ryan E., additional, Gaglani, Manjusha, additional, Clipper, Lydia, additional, Flannery, Brendan, additional, and Wisniewski, Stephen R., additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results